Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) Director Ra Capital Management, L.P. acquired 1,296,296 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $13.50 per share, with a total value of $17,499,996.00. Following the acquisition, the director now owns 4,280,051 shares in the company, valued at $57,780,688.50. The trade was a 43.45 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Mineralys Therapeutics Trading Down 0.2 %
Mineralys Therapeutics stock traded down $0.03 during trading on Monday, hitting $14.22. The company had a trading volume of 636,352 shares, compared to its average volume of 301,891. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $18.29. The company’s 50 day simple moving average is $10.45 and its 200-day simple moving average is $11.94. The stock has a market cap of $708.67 million, a price-to-earnings ratio of -3.91 and a beta of 1.50.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
Institutional Trading of Mineralys Therapeutics
Analyst Upgrades and Downgrades
MLYS has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, The Goldman Sachs Group cut their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, February 13th.
Read Our Latest Stock Report on Mineralys Therapeutics
About Mineralys Therapeutics
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Featured Articles
- Five stocks we like better than Mineralys Therapeutics
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Can TikTok Stock Picks Really Make You Rich?
- Where to Find Earnings Call Transcripts
- The “Quality” Rotation: Back to Basics Investing
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.